Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Taro Kishi; Kenji Sakuma; Masakazu Hatano; Yuki Matsuda; Satoru Esumi; Nobumi Miyake; Itaru Miura; Hikaru Hori; Masaki Kato; Nakao Iwata

doi:10.1002/npr2.12376

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Taro Kishi, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Hikaru Hori, Masaki Kato, Nakao Iwata

Research output: Contribution to journal › Article

Abstract

INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p

Original language	English
Journal	Neuropsychopharmacology reports
DOIs	https://doi.org/10.1002/npr2.12376
Publication status	Published - 30-08-2023

Access to Document

10.1002/npr2.12376Licence: Unspecified

Cite this

@article{6a9ebe7376334cf5821e440877d764a4,

title = "Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.",

abstract = "INTRODUCTION: The question remains to be elucidated: {"}Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?{"} It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p ",

author = "Taro Kishi and Kenji Sakuma and Masakazu Hatano and Yuki Matsuda and Satoru Esumi and Nobumi Miyake and Itaru Miura and Hikaru Hori and Masaki Kato and Nakao Iwata",

note = "Is international journal: true",

year = "2023",

month = aug,

day = "30",

doi = "10.1002/npr2.12376",

language = "English",

journal = "Neuropsychopharmacology reports",

issn = "1340-2544",

publisher = "John Wiley & Sons Inc.",

}

TY - JOUR

T1 - Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

AU - Kishi, Taro

AU - Sakuma, Kenji

AU - Hatano, Masakazu

AU - Matsuda, Yuki

AU - Esumi, Satoru

AU - Miyake, Nobumi

AU - Miura, Itaru

AU - Hori, Hikaru

AU - Kato, Masaki

AU - Iwata, Nakao

N1 - Is international journal: true

PY - 2023/8/30

Y1 - 2023/8/30

N2 - INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p

AB - INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p

U2 - 10.1002/npr2.12376

DO - 10.1002/npr2.12376

M3 - Article

C2 - 37646475

SN - 1340-2544

JO - Neuropsychopharmacology reports

JF - Neuropsychopharmacology reports

ER -

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Abstract

Access to Document

Fingerprint

Cite this